drugset / Trial / NCT05380882
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
Phase 1
Unknown
60 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection in subjects with advanced malignancies.
Timeline
- Start
- 2022-05
- Primary completion
- 2023-04
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2930 | Unknown | 2.5 mg/kg | Intravenous |
| Subject | TQB2930 | Unknown | 5 mg/kg | Intravenous |
| Subject | TQB2930 | Unknown | 10 mg/kg | Intravenous |
| Subject | TQB2930 | Unknown | 20 mg/kg | Intravenous |
| Subject | TQB2930 | Unknown | 30 mg/kg | Intravenous |